FR08C0028I2 - - Google Patents

Info

Publication number
FR08C0028I2
FR08C0028I2 FR08C0028C FR08C0028C FR08C0028I2 FR 08C0028 I2 FR08C0028 I2 FR 08C0028I2 FR 08C0028 C FR08C0028 C FR 08C0028C FR 08C0028 C FR08C0028 C FR 08C0028C FR 08C0028 I2 FR08C0028 I2 FR 08C0028I2
Authority
FR
France
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR08C0028C
Other languages
French (fr)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Astellas Pharma Inc
Original Assignee
Astellas Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26305774&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR08C0028(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB9420425A external-priority patent/GB9420425D0/en
Priority claimed from GBGB9508745.8A external-priority patent/GB9508745D0/en
Application filed by Astellas Pharma Inc filed Critical Astellas Pharma Inc
Publication of FR08C0028I1 publication Critical patent/FR08C0028I1/fr
Application granted granted Critical
Publication of FR08C0028I2 publication Critical patent/FR08C0028I2/fr
Active legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50Cyclic peptides containing at least one abnormal peptide link
    • C07K7/54Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
    • C07K7/56Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring the cyclisation not occurring through 2,4-diamino-butanoic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10Antimycotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
FR08C0028C 1994-10-07 2008-06-27 Active FR08C0028I2 (enExample)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB9420425A GB9420425D0 (en) 1994-10-07 1994-10-07 New compound
GBGB9508745.8A GB9508745D0 (en) 1995-04-28 1995-04-28 New compound
PCT/JP1995/001983 WO1996011210A1 (en) 1994-10-07 1995-09-29 Cyclic hexapeptides having antibiotic activity

Publications (2)

Publication Number Publication Date
FR08C0028I1 FR08C0028I1 (enExample) 2008-08-15
FR08C0028I2 true FR08C0028I2 (enExample) 2009-11-20

Family

ID=26305774

Family Applications (1)

Application Number Title Priority Date Filing Date
FR08C0028C Active FR08C0028I2 (enExample) 1994-10-07 2008-06-27

Country Status (26)

Country Link
US (2) US6107458A (enExample)
EP (1) EP0788511B1 (enExample)
JP (2) JP2897427B2 (enExample)
KR (1) KR100353303B1 (enExample)
CN (1) CN1203089C (enExample)
AR (1) AR041770A1 (enExample)
AT (1) ATE229541T1 (enExample)
AU (1) AU696949B2 (enExample)
BR (2) BRPI9504791B8 (enExample)
CA (1) CA2202058C (enExample)
DE (2) DE122008000025I2 (enExample)
DK (1) DK0788511T3 (enExample)
ES (1) ES2187575T3 (enExample)
FI (1) FI119988B (enExample)
FR (1) FR08C0028I2 (enExample)
HU (1) HU228151B1 (enExample)
IL (1) IL115484A (enExample)
LU (1) LU91452I2 (enExample)
MX (1) MX9702531A (enExample)
NL (1) NL300352I2 (enExample)
NO (2) NO328483B1 (enExample)
OA (1) OA10475A (enExample)
PT (1) PT788511E (enExample)
RU (1) RU2165423C2 (enExample)
TR (1) TR199501229A2 (enExample)
WO (1) WO1996011210A1 (enExample)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5696084A (en) * 1996-08-16 1997-12-09 Abbott Laboratories Amino-lipopetide antifungal agents
AUPO371596A0 (en) * 1996-11-19 1996-12-12 Fujisawa Pharmaceutical Co., Ltd. New compound
AUPO381496A0 (en) * 1996-11-25 1996-12-19 Fujisawa Pharmaceutical Co., Ltd. New compound
WO1998057923A1 (en) * 1997-06-18 1998-12-23 Fujisawa Pharmaceutical Co., Ltd. New production process
IL137494A0 (en) * 1998-02-09 2001-07-24 Fujisawa Pharmaceutical Co Polypeptide compounds, process for the preparation thereof and pharmaceutical compositions containing the same
AU756792B2 (en) * 1998-02-09 2003-01-23 Fujisawa Pharmaceutical Co., Ltd. New compound
JP4854855B2 (ja) * 1999-02-11 2012-01-18 エミスフェアー・テクノロジーズ・インク オキサジアゾール化合物及び活性剤をデリバリーするための組成物
US7084279B1 (en) * 1999-02-11 2006-08-01 Emisphere Technologies Inc. Oxadiazole compounds and compositions for delivering active agents
AUPP999799A0 (en) 1999-04-27 1999-05-20 Fujisawa Pharmaceutical Co., Ltd. New compound
AUPQ066399A0 (en) 1999-05-31 1999-06-24 Fujisawa Pharmaceutical Co., Ltd. Antifungal combination use
TWI233805B (en) * 1999-07-01 2005-06-11 Fujisawa Pharmaceutical Co Stabilized pharmaceutical composition in lyophilized form as antifungal agent
AU6564000A (en) 1999-07-27 2001-02-13 Aventis Pharma Deutschland Gmbh Novel cyclohexapeptide compounds, processes for their production and their use as a pharmaceutical
AUPQ462399A0 (en) * 1999-12-13 2000-01-13 Fujisawa Pharmaceutical Co., Ltd. New use
TWI250992B (en) * 2000-02-21 2006-03-11 Astellas Pharma Inc Polypeptide compounds for the prophylactic and/or therapeutic treatment of infectious diseases caused by pathogenic microorganisms
ES2191516B1 (es) * 2000-07-28 2005-01-01 Consejo Superior De Investigaciones Cientificas Antibioticos antifungicos de naturaleza peptidica inhibidores de la germinacion y el crecimiento de hongos fitopatogenos.
AUPQ938700A0 (en) * 2000-08-14 2000-09-07 Fujisawa Pharmaceutical Co., Ltd. Antifungal combination use
KR100777169B1 (ko) 2001-01-29 2007-11-16 시오노기세이야쿠가부시키가이샤 5-메틸-1-페닐-2-(1h)-피리돈을 활성 성분으로서함유하는 의약 제제
JP2005053782A (ja) * 2001-08-31 2005-03-03 Fujisawa Pharmaceut Co Ltd 環状リポペプチド化合物の新規結晶
EP1490090A4 (en) 2002-02-22 2006-09-20 New River Pharmaceuticals Inc SYSTEMS FOR DELIVERING ACTIVE AGENTS AND METHODS FOR PROTECTING AND DELIVERING ACTIVE AGENTS
JP4784093B2 (ja) * 2002-08-08 2011-09-28 アステラス製薬株式会社 イソオキサゾリル安息香酸の製造法
AU2003903205A0 (en) * 2003-06-23 2003-07-10 Fujisawa Pharmaceutical Co., Ltd. New compound
EP1654036B1 (en) 2003-07-22 2007-12-26 Theravance, Inc. Use of an echinocandin antifungal agent in combination with a glycopeptide antibacterial agent
US20070010655A1 (en) * 2003-09-05 2007-01-11 Antia Firoz D Stationary phases and a purification process using the stationary phases
CA2551037A1 (en) * 2003-09-22 2005-03-31 Banyu Pharmaceutical Co., Ltd. Novel piperidine derivative
US7476673B2 (en) * 2003-12-30 2009-01-13 Allergan, Inc. Disubstituted chalcone oximes as selective agonists of RARγ retinoid receptors
WO2005112913A1 (en) * 2004-05-20 2005-12-01 The Scripps Research Institute Transthyretin stabilization
AU2005286647A1 (en) 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-CoA desaturase inhibitors
WO2006101521A2 (en) 2004-09-20 2006-09-28 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors
AU2005286846A1 (en) 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as therapeutic agents
AR051026A1 (es) 2004-09-20 2006-12-13 Xenon Pharmaceuticals Inc Derivados heterociclicos y su uso como inhibidores de la estearoil-coa desaturasa
EP2316458A1 (en) 2004-09-20 2011-05-04 Xenon Pharmaceuticals Inc. Pyridazine derivatives for inhibiting human stearoyl-coa-desaturase
US7951805B2 (en) 2004-09-20 2011-05-31 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as mediators of stearoyl-CoA desaturase
US8071603B2 (en) 2004-09-20 2011-12-06 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-CoA desaturase inhibitors
EP2939674A1 (en) * 2004-10-13 2015-11-04 PTC Therapeutics, Inc. Compounds for nonsense suppression, and methods for their use
JP2009513563A (ja) 2005-06-03 2009-04-02 ゼノン・ファーマシューティカルズ・インコーポレイテッド ヒトのステアロイル−CoAデサチュラーゼ阻害剤としてのアミノチアゾール誘導体
KR20080066938A (ko) * 2005-10-07 2008-07-17 깃세이 야쿠힌 고교 가부시키가이샤 질소 함유 복소환 화합물 및 그것을 함유하는 의약 조성물
CN101516387B (zh) * 2006-07-26 2014-06-04 桑多斯股份公司 卡泊芬净制剂
US8853392B2 (en) 2007-06-03 2014-10-07 Vanderbilt University Benzamide mGluR5 positive allosteric modulators and methods of making and using same
ES2542849T3 (es) 2007-08-13 2015-08-12 Monsanto Technology Llc Composiciones y procedimientos de control de nematodos
CN101861330A (zh) * 2007-10-29 2010-10-13 安斯泰来制药有限公司 多肽化合物
US8034806B2 (en) 2007-11-02 2011-10-11 Vanderbilt University Bicyclic mGluR5 positive allosteric modulators and methods of making and using same
EP2300442A2 (en) * 2008-06-24 2011-03-30 Irm Llc Compounds and methods for modulating g protein-coupled receptors
US9394340B2 (en) 2009-03-24 2016-07-19 Cadila Healthcare Limited Purification process for lipopeptides
BR112013023531A2 (pt) * 2011-04-04 2016-12-06 Xellia Pharmaceuticals Aps processo de um único vaso para a fabricação de micafungina ou de um sal desta
ES2547827T3 (es) 2011-04-20 2015-10-08 Axellia Pharmaceuticals Aps Procedimiento para la purificación de la micafungina
CN102775476B (zh) 2011-05-12 2015-01-07 上海天伟生物制药有限公司 一种米卡芬净钠盐的制备方法
US9156830B2 (en) 2011-05-17 2015-10-13 Shionogi & Co., Ltd. Heterocyclic compounds
US20140329989A1 (en) * 2011-09-09 2014-11-06 Sandoz Ag Preparation of micafungin intermediates
CN102627688B (zh) 2012-03-30 2014-12-31 上海天伟生物制药有限公司 一种高纯度环肽化合物及其制备方法和用途
CN102659930B (zh) 2012-03-30 2014-04-23 上海天伟生物制药有限公司 一种高纯度环肽类物质的晶体及其制备方法和用途
CN102627689B (zh) * 2012-03-30 2014-08-06 上海天伟生物制药有限公司 一种环肽类化合物的水合物及其制备方法和用途
US10183973B2 (en) * 2014-05-29 2019-01-22 Shanghai Techwell Biopharmaceutical Co., Ltd. Solvate of cyclic peptide compound, preparation method for same, and uses thereof
JP7109189B2 (ja) * 2014-05-29 2022-07-29 シャンハイ テックウェル バイオファーマシューティカル カンパニー リミテッド シクロペプチド系化合物の組成物およびその製造方法と使用
WO2016056023A2 (en) * 2014-10-07 2016-04-14 Alaparthi Lakshmi Prasad Intermediates and processes to prepare micafungin
CA2937365C (en) 2016-03-29 2018-09-18 F. Hoffmann-La Roche Ag Granulate formulation of 5-methyl-1-phenyl-2-(1h)-pyridone and method of making the same
AU2017376960B2 (en) 2016-12-16 2023-12-14 Baxter Healthcare Sa Micafungin compositions
EP3485873A1 (en) 2017-11-17 2019-05-22 Cadila Healthcare Limited Stable pharmaceutical injectable compositions of micafungin
CN113087775B (zh) * 2018-05-31 2022-07-08 杭州中美华东制药有限公司 米卡芬净钠新晶型ii及其制备方法
WO2020013116A1 (ja) * 2018-07-10 2020-01-16 京都薬品工業株式会社 Ptp-1b阻害剤およびその用途
CN110734408A (zh) * 2019-10-22 2020-01-31 重庆康乐制药有限公司 一种米卡芬净类衍生物侧链中间体的制备方法
CN115785226A (zh) * 2021-09-09 2023-03-14 上海天伟生物制药有限公司 一种棘白菌素药物杂质及其制备、纯化方法和应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU1574603A1 (ru) * 1988-08-11 1990-06-30 Ивановский Химико-Технологический Институт Способ получени мезо-тетраарилоктаметилпорфиринов
IE912046A1 (en) * 1990-06-18 1991-12-18 Fujisawa Pharmaceutical Co New polypeptide compound and a process for preparation¹thereof
MY136593A (en) * 1992-03-19 2008-10-31 Lilly Co Eli Cyclic peptide antifungal agents and process for preparation thereof

Also Published As

Publication number Publication date
US6265536B1 (en) 2001-07-24
WO1996011210A1 (en) 1996-04-18
KR970707150A (ko) 1997-12-01
NO2010016I2 (no) 2011-10-17
KR100353303B1 (ko) 2003-01-15
AU3578095A (en) 1996-05-02
JPH10324695A (ja) 1998-12-08
JP2897427B2 (ja) 1999-05-31
US6107458A (en) 2000-08-22
AU696949B2 (en) 1998-09-24
EP0788511A1 (en) 1997-08-13
DE69529172T2 (de) 2003-04-17
DE69529172D1 (de) 2003-01-23
JP3518665B2 (ja) 2004-04-12
LU91452I2 (fr) 2008-08-04
PT788511E (pt) 2003-04-30
NO971544D0 (no) 1997-04-04
EP0788511B1 (en) 2002-12-11
TR199501229A2 (tr) 1996-07-21
FI971397A0 (fi) 1997-04-04
FI971397L (fi) 1997-05-27
NL300352I1 (nl) 2008-08-01
OA10475A (en) 2002-04-08
FR08C0028I1 (enExample) 2008-08-15
IL115484A (en) 2000-07-16
CN1168675A (zh) 1997-12-24
CN1203089C (zh) 2005-05-25
ES2187575T3 (es) 2003-06-16
HU228151B1 (en) 2012-12-28
DE122008000025I1 (de) 2008-08-21
NO2010016I1 (no) 2010-08-16
BR9504791A (pt) 1996-10-22
CA2202058A1 (en) 1996-04-18
NL300352I2 (nl) 2008-11-03
JPH10507174A (ja) 1998-07-14
IL115484A0 (en) 1996-01-19
DK0788511T3 (da) 2003-03-31
CA2202058C (en) 2007-11-06
NO328483B1 (no) 2010-03-01
MX9702531A (es) 1997-06-28
HK1004136A1 (en) 1998-11-20
BR9504791B1 (pt) 2010-10-05
HUT77736A (hu) 1998-07-28
NO971544L (no) 1997-06-04
FI119988B (fi) 2009-05-29
AR041770A1 (es) 2005-06-01
RU2165423C2 (ru) 2001-04-20
ATE229541T1 (de) 2002-12-15
BRPI9504791B8 (pt) 2019-12-31
DE122008000025I2 (de) 2011-02-17

Similar Documents

Publication Publication Date Title
TW287110B (enExample)
TW281822B (enExample)
FR08C0028I2 (enExample)
TW267274B (enExample)
DK105996A (enExample)
BR9508234A (enExample)
EP0712259A3 (enExample)
TW277204B (enExample)
TW279989B (enExample)
BY1704C1 (enExample)
FR2725446B1 (enExample)
ITBZ950004V0 (enExample)
IN181697B (enExample)
ITMI952257A0 (enExample)
GB2295374B8 (enExample)
TW268110B (enExample)
IN185440B (enExample)
ECSDI940194S (enExample)
DK40195A (enExample)
IN190713B (enExample)
ECSDI940181S (enExample)
IN190248B (enExample)
NO941553D0 (enExample)
IN184323B (enExample)
BR7402097U (enExample)